Cargando…

Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study

PURPOSE: The Quality of Life Alzheimer’s Disease Scale (QoL-AD) is commonly used to assess disease specific health-related quality of life (HRQoL) as rated by patients and their carers. For cost-effectiveness analyses, utilities based on the EQ-5D are often required. We report a new mapping algorith...

Descripción completa

Detalles Bibliográficos
Autores principales: Rombach, Ines, Iftikhar, Marvi, Jhuti, Gurleen S., Gustavsson, Anders, Lecomte, Pascal, Belger, Mark, Handels, Ron, Castro Sanchez, Amparo Y., Kors, Jan, Hopper, Louise, Olde Rikkert, Marcel, Selbæk, Geir, Stephan, Astrid, Sikkes, Sietske A. M., Woods, Bob, Gonçalves-Pereira, Manuel, Zanetti, Orazio, Ramakers, Inez H. G. B., Verhey, Frans R. J., Gallacher, John, Actifcare Consortium, LeARN Consortium, Landeiro, Filipa, Gray, Alastair M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952290/
https://www.ncbi.nlm.nih.gov/pubmed/33068236
http://dx.doi.org/10.1007/s11136-020-02670-8
_version_ 1783663696007921664
author Rombach, Ines
Iftikhar, Marvi
Jhuti, Gurleen S.
Gustavsson, Anders
Lecomte, Pascal
Belger, Mark
Handels, Ron
Castro Sanchez, Amparo Y.
Kors, Jan
Hopper, Louise
Olde Rikkert, Marcel
Selbæk, Geir
Stephan, Astrid
Sikkes, Sietske A. M.
Woods, Bob
Gonçalves-Pereira, Manuel
Zanetti, Orazio
Ramakers, Inez H. G. B.
Verhey, Frans R. J.
Gallacher, John
Actifcare Consortium
LeARN Consortium
Landeiro, Filipa
Gray, Alastair M.
author_facet Rombach, Ines
Iftikhar, Marvi
Jhuti, Gurleen S.
Gustavsson, Anders
Lecomte, Pascal
Belger, Mark
Handels, Ron
Castro Sanchez, Amparo Y.
Kors, Jan
Hopper, Louise
Olde Rikkert, Marcel
Selbæk, Geir
Stephan, Astrid
Sikkes, Sietske A. M.
Woods, Bob
Gonçalves-Pereira, Manuel
Zanetti, Orazio
Ramakers, Inez H. G. B.
Verhey, Frans R. J.
Gallacher, John
Actifcare Consortium
LeARN Consortium
Landeiro, Filipa
Gray, Alastair M.
author_sort Rombach, Ines
collection PubMed
description PURPOSE: The Quality of Life Alzheimer’s Disease Scale (QoL-AD) is commonly used to assess disease specific health-related quality of life (HRQoL) as rated by patients and their carers. For cost-effectiveness analyses, utilities based on the EQ-5D are often required. We report a new mapping algorithm to obtain EQ-5D indices when only QoL-AD data are available. METHODS: Different statistical models to estimate utility directly, or responses to individual EQ-5D questions (response mapping) from QoL-AD, were trialled for patient-rated and proxy-rated questionnaires. Model performance was assessed by root mean square error and mean absolute error. RESULTS: The response model using multinomial regression including age and sex, performed best in both the estimation dataset and an independent dataset. CONCLUSIONS: The recommended mapping algorithm allows researchers for the first time to estimate EQ-5D values from QoL-AD data, enabling cost-utility analyses using datasets where the QoL-AD but no utility measures were collected. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11136-020-02670-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7952290
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-79522902021-03-28 Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study Rombach, Ines Iftikhar, Marvi Jhuti, Gurleen S. Gustavsson, Anders Lecomte, Pascal Belger, Mark Handels, Ron Castro Sanchez, Amparo Y. Kors, Jan Hopper, Louise Olde Rikkert, Marcel Selbæk, Geir Stephan, Astrid Sikkes, Sietske A. M. Woods, Bob Gonçalves-Pereira, Manuel Zanetti, Orazio Ramakers, Inez H. G. B. Verhey, Frans R. J. Gallacher, John Actifcare Consortium LeARN Consortium Landeiro, Filipa Gray, Alastair M. Qual Life Res Article PURPOSE: The Quality of Life Alzheimer’s Disease Scale (QoL-AD) is commonly used to assess disease specific health-related quality of life (HRQoL) as rated by patients and their carers. For cost-effectiveness analyses, utilities based on the EQ-5D are often required. We report a new mapping algorithm to obtain EQ-5D indices when only QoL-AD data are available. METHODS: Different statistical models to estimate utility directly, or responses to individual EQ-5D questions (response mapping) from QoL-AD, were trialled for patient-rated and proxy-rated questionnaires. Model performance was assessed by root mean square error and mean absolute error. RESULTS: The response model using multinomial regression including age and sex, performed best in both the estimation dataset and an independent dataset. CONCLUSIONS: The recommended mapping algorithm allows researchers for the first time to estimate EQ-5D values from QoL-AD data, enabling cost-utility analyses using datasets where the QoL-AD but no utility measures were collected. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11136-020-02670-8) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-10-17 2021 /pmc/articles/PMC7952290/ /pubmed/33068236 http://dx.doi.org/10.1007/s11136-020-02670-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Rombach, Ines
Iftikhar, Marvi
Jhuti, Gurleen S.
Gustavsson, Anders
Lecomte, Pascal
Belger, Mark
Handels, Ron
Castro Sanchez, Amparo Y.
Kors, Jan
Hopper, Louise
Olde Rikkert, Marcel
Selbæk, Geir
Stephan, Astrid
Sikkes, Sietske A. M.
Woods, Bob
Gonçalves-Pereira, Manuel
Zanetti, Orazio
Ramakers, Inez H. G. B.
Verhey, Frans R. J.
Gallacher, John
Actifcare Consortium
LeARN Consortium
Landeiro, Filipa
Gray, Alastair M.
Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study
title Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study
title_full Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study
title_fullStr Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study
title_full_unstemmed Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study
title_short Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study
title_sort obtaining eq-5d-5l utilities from the disease specific quality of life alzheimer’s disease scale: development and results from a mapping study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952290/
https://www.ncbi.nlm.nih.gov/pubmed/33068236
http://dx.doi.org/10.1007/s11136-020-02670-8
work_keys_str_mv AT rombachines obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT iftikharmarvi obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT jhutigurleens obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT gustavssonanders obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT lecomtepascal obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT belgermark obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT handelsron obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT castrosanchezamparoy obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT korsjan obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT hopperlouise obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT olderikkertmarcel obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT selbækgeir obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT stephanastrid obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT sikkessietskeam obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT woodsbob obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT goncalvespereiramanuel obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT zanettiorazio obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT ramakersinezhgb obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT verheyfransrj obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT gallacherjohn obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT actifcareconsortium obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT learnconsortium obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT landeirofilipa obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT grayalastairm obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy
AT obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy